抗真菌薬 - 世界市場の考察、競合情勢、市場予測（2030年）

世界の抗真菌剤の市場規模は、2022年に146億3,688万米ドル、2030年までに191億6,267万米ドルに達し、2024年～2030年の予測期間にCAGRで4.65%で成長すると見込まれています。市場は、爪真菌症、白癬、膣カンジダ症、アスペルギルス症、口腔、咽頭、食道のカンジダ感染症、眼科真菌症などのさまざまな真菌感染症の有病率の増加により、大幅な市場成長を示しています。さらに、一般用医薬品としての抗真菌薬の入手可能性の高まりや、抗真菌薬のジェネリック医薬品への需要の急増、世界の院内感染の急増、侵襲性真菌感染症の治療に向けた合成および半合成アゾール系化合物の開発などの医薬品の技術革新の増加などが、抗真菌薬の需要の急増に寄与する見込みです。同様に、薬剤の承認および上市の急増に伴う研究開発活動の増加や、市場における主要企業のプレゼンスは、市場における抗真菌薬の必要性を生み出します。したがって、市場は2024年～2030年の予測期間に大幅なCAGRで成長すると推定されます。

抗真菌薬の市場力学

Global Action for Fungal Infectionsの最新調査によると、世界全体で年間3億人以上が深刻な真菌感染症に罹患しています。また、同資料によると、侵襲性アスペルギルス症は100万人近くが罹患しており、侵襲性カンジダ症は年間75万人近くが罹患しています。

さらに、院内感染の流行が予測期間に抗真菌薬市場の促進要因となる見込みです。世界保健機関（WHO）は2022年、高所得国では集中治療室患者の約30％が少なくとも1件の医療関連感染に罹患していると発表しています。一方、低中所得国では、集中治療室での感染頻度は高所得国の2～3倍です。このように、院内感染の増加は抗真菌薬の需要を促進すると予測されます。

さらに、多くの真菌感染症に対する意識の高まり、OTC抗真菌薬の急増、発展途上国における抗真菌薬の使用の増加などが、抗真菌薬の成長に寄与します。また、クロトリマゾール、エコナゾール、ケトコナゾール、ミコナゾール、アモロルフィンなどのOTC医薬品の普及に伴い、多くの患者がOTC医薬品を服用していることがわかっています。

したがって、2024年～2030年の予測期間を通じて、上記の要因が総合的に抗真菌薬市場全体を牽引します。

しかし、抗真菌薬に対する耐性菌の増加や、抗真菌薬の副作用、厳格な規制承認プロセスが、抗真菌薬市場の成長を中断する可能性があります。

抗真菌薬市場は、COVID-19パンデミック期間に中程度の影響を受けました。パンデミックの初期段階では、厳しいロックダウン規則が適用され、製造と供給が中断されたため、抗真菌薬の売上は崩壊に見舞われました。しかし、政府はパンデミック中、医薬品や薬剤を緊急用製品に分類し、それによって需要や売上が増加しました。さらに、オンライン薬局の関与により、多くのOTC医薬品の売上が増加し、抗真菌薬市場に影響を与えました。同様に、ロックダウン規制の緩和、リソースとサプライチェーンの好転、大衆へのワクチン投与、精神障害の治療率の増加に伴い、抗真菌薬の需要が増加し、2022年～2028年の予測期間にも同様の需要が見込まれます。

抗真菌薬市場のセグメント分析

抗真菌薬市場の薬剤タイプセグメントでは、2023年にクロトリマゾールセグメントが大きな収益シェアを占めると予測されています。これは主に、世界中で真菌感染症の有病率が増加しているためです。また、このセグメントに関連する主要企業による発売の拡大や戦略的投資、その他の活動も、予測期間にその市場を後押しします。さらに、クロトリマゾールの広範な用途の輪は、予測期間にその市場を推進することが見込まれます。

例えば、アゾール系薬剤は、鵞口瘡、イースト菌感染症、カンジダ症、アスペルギルス症、癜風、水虫、いんきんたむし、全身性真菌症、脂漏性皮膚炎などの治療に使用されます。

当レポートでは、世界の抗真菌薬市場について調査分析し、市場規模と予測、促進要因と課題、企業と製品のプロファイルなどを提供しています。

目次

第1章 抗真菌薬市場レポートのイントロダクション

第2章 抗真菌薬市場のエグゼクティブサマリー

• 調査範囲
• 市場の概要
• 競合の評価

第3章 規制分析

第4章 抗真菌薬市場の主な要因の分析

• 抗真菌薬市場の促進要因
• 抗真菌薬市場の抑制要因と課題
• 抗真菌薬市場の機会

第5章 抗真菌薬市場のポーターのファイブフォース分析

第6章 抗真菌薬市場に対するCOVID-19の影響分析

第7章 抗真菌薬市場のレイアウト

• 適応症別
  • アスペルギルス症
  • 皮膚糸状菌症
  • カンジダ症
  • その他
• 薬剤タイプ別
  • エキノカンジン
  • アゾール
  • ポリエン
  • アリルアミン
• 剤形別
  • 粉末
  • 軟膏
  • 錠剤
• 地域
  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域

第8章 抗真菌薬市場の企業と製品のプロファイル

• Abbott.
• Bayer AG
• GSK plc.
• Merck & Co., Inc.
• Cadila Pharmaceuticals.
• Glenmark
• SCYNEXIS, Inc.
• Astellas Pharma d.o.o.
• Arcadia Consumer Healthcare
• Novartis AG
• Pfizer Inc.
• Leadiant Biosciences, Inc.
• Sun Pharmaceutical Industries Ltd.
• Viatris Inc.
• Sanofi
• Gilead Sciences, Inc.
• Apotex Inc.
• Aurobindo Pharma USA
• Cipla Inc.
• Dr. Reddy's Laboratories Ltd.

第9章 KOLの見解

第10章 プロジェクトのアプローチ

第11章 DelveInsightについて

第12章 免責事項、お問い合わせ

List of Tables

• Table 1: Competitive Analysis
• Table 2: COVID-19 Impact Analysis on Antifungal Drugs Market
• Table 3: Antifungal Drugs Market Analysis in Global (2021-2030)
• Table 4: Antifungal Drugs Market Analysis in Global by Indication (2021-2030)
• Table 5: Antifungal Drugs Market Analysis in Global by Drug Type (2021-2030)
• Table 6: Antifungal Drugs Market Analysis in Global by Dosage Form (2021-2030)
• Table 7: Antifungal Drugs Market Analysis in Global by Geography (2021-2030)
• Table 8: Antifungal Drugs Market Analysis in North America (2021-2030)
• Table 9: Antifungal Drugs Market Analysis in North America by Country (2021-2030)
• Table 10: Antifungal Drugs Market Analysis in the US (2021-2030)
• Table 11: Antifungal Drugs Market Analysis in Canada (2021-2030)
• Table 12: Antifungal Drugs Market Analysis in Mexico (2021-2030)
• Table 13: Antifungal Drugs Market Analysis in Europe (2021-2030)
• Table 14: Antifungal Drugs Market Analysis in Europe by Country (2021-2030)
• Table 15: Antifungal Drugs Market Analysis in France (2021-2030)
• Table 16: Antifungal Drugs Market Analysis in Germany (2021-2030)
• Table 17: Antifungal Drugs Market Analysis in the UK (2021-2030)
• Table 18: Antifungal Drugs Market Analysis in Italy (2021-2030)
• Table 19: Antifungal Drugs Market Analysis in Spain (2021-2030)
• Table 20: Antifungal Drugs Market Analysis in the Rest of Europe (2021-2030)
• Table 21: Antifungal Drugs Market Analysis in Asia-Pacific (2021-2030)
• Table 22: Antifungal Drugs Market Analysis in Asia-Pacific by Country (2021-2030)
• Table 23: Antifungal Drugs Market Analysis in China (2021-2030)
• Table 24: Antifungal Drugs Market Analysis in Japan (2021-2030)
• Table 25: Antifungal Drugs Market Analysis in India (2021-2030)
• Table 26: Antifungal Drugs Market Analysis in Australia (2021-2030)
• Table 27: Antifungal Drugs Market Analysis in South Korea (2021-2030)
• Table 28: Antifungal Drugs Market Analysis in the Rest of Asia-Pacific (2021-2030)
• Table 29: Antifungal Drugs Market Analysis in the Rest of the World (2021-2030)
• Table 30: Antifungal Drugs Market Analysis in the Rest of the World by Region (2021-2030)
• Table 31: Antifungal Drugs Market Analysis in the Middle East (2021-2030)
• Table 32: Antifungal Drugs Market Analysis in Africa (2021-2030)
• Table 33: Antifungal Drugs Market Analysis in South America (2021-2030)

List of Figures

• Figure 1: Competitive Analysis
• Figure 2: COVID-19 Impact Analysis on Antifungal Drugs Market
• Figure 3: Antifungal Drugs Market Analysis in Global (2021-2030)
• Figure 4: Antifungal Drugs Market Analysis in Global by Indication (2021-2030)
• Figure 5: Antifungal Drugs Market Analysis in Global by Drug Type (2021-2030)
• Figure 6: Antifungal Drugs Market Analysis in Global by Dosage Form (2021-2030)
• Figure 7: Antifungal Drugs Market Analysis in Global by Geography (2021-2030)
• Figure 8: Antifungal Drugs Market Analysis in North America (2021-2030)
• Figure 9: Antifungal Drugs Market Analysis in North America by Country (2021-2030)
• Figure 10: Antifungal Drugs Market Analysis in the US (2021-2030)
• Figure 11: Antifungal Drugs Market Analysis in Canada (2021-2030)
• Figure 12: Antifungal Drugs Market Analysis in Mexico (2021-2030)
• Figure 13: Antifungal Drugs Market Analysis in Europe (2021-2030)
• Figure 14: Antifungal Drugs Market Analysis in Europe by Country (2021-2030)
• Figure 15: Antifungal Drugs Market Analysis in France (2021-2030)
• Figure 16: Antifungal Drugs Market Analysis in Germany (2021-2030)
• Figure 17: Antifungal Drugs Market Analysis in the UK (2021-2030)
• Figure 18: Antifungal Drugs Market Analysis in Italy (2021-2030)
• Figure 19: Antifungal Drugs Market Analysis in Spain (2021-2030)
• Figure 20: Antifungal Drugs Market Analysis in the Rest of Europe (2021-2030)
• Figure 21: Antifungal Drugs Market Analysis in Asia-Pacific (2021-2030)
• Figure 22: Antifungal Drugs Market Analysis in Asia-Pacific by Country (2021-2030)
• Figure 23: Antifungal Drugs Market Analysis in China (2021-2030)
• Figure 24: Antifungal Drugs Market Analysis in Japan (2021-2030)
• Figure 25: Antifungal Drugs Market Analysis in India (2021-2030)
• Figure 26: Antifungal Drugs Market Analysis in Australia (2021-2030)
• Figure 27: Antifungal Drugs Market Analysis in South Korea (2021-2030)
• Figure 28: Antifungal Drugs Market Analysis in the Rest of Asia-Pacific (2021-2030)
• Figure 29: Antifungal Drugs Market Analysis in the Rest of the World (2021-2030)
• Figure 30: Antifungal Drugs Market Analysis in the Rest of the World by Region (2021-2030)
• Figure 31: Antifungal Drugs Market Analysis in the Middle East (2021-2030)
• Figure 32: Antifungal Drugs Market Analysis in Africa (2021-2030)
• Figure 33: Antifungal Drugs Market Analysis in South America (2021-2030)
• Figure 34: Market Drivers
• Figure 35: Market Barriers
• Figure 36: Market Opportunities
• Figure 37: PORTER's Five Force Analysis

Antifungal Drugs Market By Indication (Aspergillosis, Dermatophytosis, Candidiasis, And Others), By Drug Type (Echinocandins [Caspofungin, Micafungin, And Others], Azoles [Voriconazole, Posaconazole, Clotrimazole, And Others], Polyenes [Amphotericin And Others], Allylamines [Terbinafine And Others], And Others), By Dosage Form (Powder, Ointments, Tablets, And Others), and by geography is expected to advance at a respectable CAGR forecast till 2030 owing to the increasing burden of fungal infections such as fungal nail infections, ringworm, vaginal candidiasis, aspergillosis, and others and the increasing research & developmental activities with reference to the antifungal drugs across the globe

The global antifungal drugs market was valued at USD 14,636.88 million in 2022 and is likely to register a CAGR of 4.65% during the forecast period from 2024 to 2030 to reach USD 19,162.67 million by 2030. The antifungal drugs market is observing substantial market growth owing to the growing prevalence of various fungal infections such as fungal nail infections, ringworm, vaginal candidiasis, aspergillosis, candida infections of mouth, throat, and esophagus, fungal eye infections, and others. Further, the increasing availability of antifungal drugs as over-the-counter (OTC), surging demand for generic antifungal drugs, the surging incidence of nosocomial infections worldwide, increasing innovations in the drugs, such as the development of synthetic and semi-synthetic azole-based compounds for the treatment of invasive fungal infections, and others will aid in surging the demand for antifungal drugs. Likewise, the increasing research & developmental activities along with the surging drug approvals and launches, and the presence of key players in the market will create a requisite for antifungal drugs in the market. Therefore, the market for antifungal drugs is estimated to grow at a substantial CAGR during the forecast period from 2024 to 2030.

Antifungal Drugs Market Dynamics:

According to the latest study done by Global Action for Fungal Infections, globally, over 300 million people are affected with a serious fungal infection, yearly. Moreover, as per the same source, invasive aspergillosis affects nearly 1,000,000 people, and invasive candidiasis affects nearly 750,000 people yearly, worldwide.

Further, the growing prevalence of nosocomial or hospital-acquired infections will aid in propelling the market of antifungal drugs during the forecast period. The World Health Organization (WHO) in 2022 stated that in high-income countries, approximately 30% of the patients in intensive care units are affected by at least 1 healthcare-associated infection. Whereas, in middle to low-income countries the frequency of intensive care-acquired infection is 2-3 times higher than that of high-income countries. Thus, the increasing prevalence of hospital-acquired infections is anticipated to propel the demand for antifungal drugs.

Additionally, increasing awareness for many fungal infections, the surging number of over-the-counter antifungal (OTC) drugs, and increased use of antifungal drugs in developing countries, and others will thereby contribute to the growth of the antifungal drugs. Also, with the growing popularity of over-the-counter (OTC) drugs such as clotrimazole, econazole, ketoconazole, miconazole, and amorolfine, many patients are found to be taking OTC drugs.

Therefore, the factors stated above collectively will drive the overall antifungal drugs market throughout the forecast period from 2024-2030.

However, the increasing resistance to antifungal drugs, side effects of antifungal drugs, and stringent regulatory approval process may halt the market growth of antifungal drugs.

The antifungal drugs market was moderately impacted during the period of COVID- 19 pandemic. During the initial stage of the pandemic, the sale of antifungals suffered a collapse owing to the imposition of strict lockdown rules, and disruption in manufacturing, and supply. However, the government classified medicines and drugs under emergency products during the pandemic, thereby leading to an increase in their demand or sales. Moreover, with the involvement of online pharmacies, the sale of many over-the-counter medicines increased, impacting the market for antifungal drugs. Likewise, the ease of lockdown restrictions, the upturn of resources and supply chain, the administration of a vaccine to the public, and with the increasing number of treatment rates for mental disorders, the demand for antifungal drugs increases and is anticipated to do the same during the forecast period from 2022 - 2028.

Antifungal Drugs Market Segment Analysis:

Antifungal Drugs Market by Indication (Aspergillosis, Dermatophytosis, Candidiasis, and Others), Drug Type (Echinocandins [Caspofungin, Micafungin, and Others], Azoles [Voriconazole, Posaconazole, Clotrimazole, and Others], Polyenes [Amphotericin and Others], Allylamines [Terbinafine and Others], and Others), Dosage Form (Powder, Ointments, Tablets, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).

In the drug type segment of the antifungal drugs market, the clotrimazole segment is expected to have a significant revenue share in the year 2023. This was primarily owing to the increasing prevalence of fungal infections across the globe. Also, the expanding launches and strategic investments, and other activities by the key players related to the segment will support driving its market during the forecast period. Further, the wide application circle of clotrimazole is anticipated to propel its market during the forecast period.

For instance, azoles drugs are used to treat thrush, yeast infection, candidiasis, aspergillosis, tinea versicolor, athlete's foot, jock itch, ringworm, fungal infections, systemic mycosis, and seborrheic dermatitis.

Also, clotrimazole provides a broad spectrum of activity and improved safety standards. The medication has fewer side effects and improved absorption and distribution properties.

Further, various other strategic steps taken by key players in the market will help in increasing the demand for Antifungals. For instance, in June 2022, Cadila Pharmaceuticals launched a new triazole antifungal drug Posaconazole that is effective against a wide range of invasive fungal diseases. The drug was also recommended as a second-line treatment for Mucormycosis. Also, in 2019, Mayne Pharma announced the launch of the TOLSURA (SUBA-itraconazole) 65mg capsule in the United States. TOLSURA is a formulation of itraconazole that has been shown to treat fungal infections of the system, including blastomycosis, histoplasmosis, aspergillosis, and others.

Therefore, owing to the above-mentioned factors, the demand for azoles upsurges, thereby the category is expected to witness considerable growth eventually contributing to the overall growth of the global antifungal drugs market during the forecast period.

North America is expected to dominate the overall Antifungal Drugs Market:

Among all the regions, North America is expected to dominate the global antifungal drugs market in the year 2023 and is expected to do the same during the forecast period from 2024-2030.

This can be ascribed to the increasing demand for antifungal drugs among the patients in the region owing to the increasing prevalence of various fungal infections such as athlete's foot, jock itch, ringworm, Aspergillosis, Candidiasis, and others. Further, the increasing number of antifungal drugs as over-the-counter (OTC), the rising awareness about the treatment of fungal infections, and the presence of key domicile players contribute to the growth of the antifungal drugs market in North America during the forecast period from 2022 - 2028.

For instance, as per the Centers for Disease Control and Prevention (CDC) 2022, an estimated 1.4 million outpatient visits for vaginal candidiasis occur annually, in the United States.

Additionally, according to the Centers for Disease Control and Prevention (CDC), resistance to certain strains of Candida (which occurs as a common cause of blood-related infections in the United States) has been noted in the United States and about 7% of all Candida bloodstream tests are not resistant to fluconazole.

Though, resistance to echinocandin has increased. In addition, drug-resistant strains are also prevalent in the region. Also, the number of aging people is growing in the United States, which may act as a supportive factor for market growth. According to the World Population Aging 2019 report, about 53,340 people were 65 years and older by 2019, and that number is expected to reach 70,842 by 2030, representing about 20% of the country's population. This population is more susceptible to chronic diseases, such as cancer, thus damaging the immune system. Hence, the population could be more susceptible to fungal infections, which will drive the need for anti-fungal drugs in the region. This population is more susceptible to chronic diseases, thus, putting the immune system at risk. Therefore, the population is more susceptible to fungal infections, which will drive the need for anti-fungal drugs in the United States.

Furthermore, various players are conducting clinical trials on antifungal drugs, which will create an opportunity for the market to grow in the upcoming years. For instance, Scynexis, Inc., a United States-based biotech company, is conducting a multicenter, open-label, non-comparator, single-arm study to evaluate the efficacy and safety of ibrexafungerp in patients >= 18 years of age with a documented invasive and/or severe fungal disease that has been intolerant or refractory (rIFI) to Standard of Care (SoC) antifungal treatment.

Moreover, the market players in the country are continuously concentrating on the development of novel drugs to tackle fungal infections using antifungal drugs, and they are also adopting various strategies to develop better drugs with reduced side effects. Thus, this is likely to drive the market in the region. For instance, in May 2022, the US Food and Drug Administration approved Vivjoa (oteseconazole) by Mycovia Pharmaceuticals' azole antifungal for chronic vaginal yeast infection. Oteseconazole, a tetrazole, is designed to inhibit fungal CYP51 enzymes but not human CYP enzymes. Human enzyme inhibition accounts for the side effects of other azole antifungals, thus reducing the side effects.

Therefore, the interplay of the aforementioned factors above would provide a conducive growth environment for antifungal drugs in the North America.

Antifungal Drugs Market Key Players:

Some of the key market players operating in the antifungal drugs market include Abbott., Bayer AG, GSK plc., Merck & Co., Inc., Cadila Pharmaceuticals., Glenmark, SCYNEXIS, Inc., Astellas Pharma d.o.o., Arcadia Consumer Healthcare, Novartis AG, Pfizer Inc., Leadiant Biosciences, Inc., Sun Pharmaceutical Industries Ltd., Viatris Inc., Sanofi, Gilead Sciences, Inc., Apotex Inc., Aurobindo Pharma USA, Cipla Inc., Dr. Reddy's Laboratories Ltd., and others.

Recent Developmental Activities in the Antifungal Drugs Market:

In October 2022, Intas Pharmaceuticals Limited on Tuesday announced the launch of an innovative antifungal drug, Super Bioavailable Itraconazole-SB 100mg under the brand name - Itaspor-SB Forte/Subawin. The drug will substantially reduce the cost of the therapy for fungal infection, and also is expected to improve patient compliance and reduce the Doctor's counseling time. It will reduce dosing to half, Intas said in an announcement.

In May 2022 announced the launch of the new and improved range of Canesten, their anti-fungal treatment solution in India.

In June 2022, Scynexis announced the approval of Brexafemme by the United States Food and Drug Administration for the treatment of vaginal yeast infections.

Key Takeaways from the Antifungal Drugs Market Report Study

• Market size analysis for current antifungal drugs market size (2023), and market forecast for 5 years (2024-2030)
• The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the antifungal drugs market.
• Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
• Key companies dominating the global antifungal drugs market.
• Various opportunities available for the other competitor in the antifungal drugs market space.
• What are the top-performing segments in 2023? How these segments will perform in 2030.
• Which are the top-performing regions and countries in the current antifungal drugs market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for antifungal drugs market growth in the coming future?

Target Audience who can be benefited from this Antifungal Drugs Market Report Study

• Antifungal drugs providers
• Research organizations and consulting companies
• Antifungal drugs -related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and Traders dealing in antifungal drugs
• Various end users who want to know more about the antifungal drugs market and the latest developments in the antifungal drugs market.

Frequently Asked Questions for the Antifungal Drugs Market:

1. What are antifungal drugs?

Antifungal drugs are prescribed for the treatment of diseases caused by various fungi such as Aspergillosis, candida, and others. These drugs work either by killing the fungal cells or stopping them from growing and multiplying. The antifungal drugs can be administered orally, or applied topically, or administer intravenously through an IV drip.

2. What is the global market for antifungal drugs?

The global antifungal drugs market was valued at USD 14,636.88 million in 2022 and is likely to register a CAGR of 4.65% during the forecast period from 2024 to 2030 to reach USD 19,162.67 million by 2030.

3. What are the drivers for the global antifungal drugs market?

The antifungal drugs market is witnessing positive market growth owing to the factors such as the growing prevalence of various fungal infections, the increasing number of antifungal drugs as over-the-counter (OTC), the surging incidence of nosocomial infections worldwide, increasing product innovations, such as the development of synthetic and semi-synthetic azole-based compounds for the treatment of invasive fungal infections, surging new drug launches and approvals, presence of key players in the market, and others will create an exigency for the antifungal drugs market.

4. Who are the key players operating in the global antifungal drugs market?

Some of the key market players operating in the antifungal drugs market include Abbott., Bayer AG, GSK plc., Merck & Co., Inc., Cadila Pharmaceuticals., Glenmark, SCYNEXIS, Inc., Astellas Pharma d.o.o., Arcadia Consumer Healthcare, Novartis AG, Pfizer Inc., Leadiant Biosciences, Inc., Sun Pharmaceutical Industries Ltd., Viatris Inc., Sanofi, Gilead Sciences, Inc., Apotex Inc., Aurobindo Pharma USA, Cipla Inc., Dr. Reddy's Laboratories Ltd., and others.

5. Which region has the highest share of the antifungal drugs market?

Among all the regions, North America is estimated to hold a significant revenue share in the global antifungal drugs market. This can be ascribed to the increasing demand for antifungal drugs among the patients in the region owing to the increasing prevalence of various fungal infections such as athlete's foot, jock itch, ringworm, Aspergillosis, Candidiasis, and others. Further, the increasing number of antifungal drugs as over-the-counter (OTC), the rising awareness about the treatment of fungal infections, and the presence of key domicile players in the region are the reasons which act as a supportive factor for the North America antifungal drugs market growth.

Table of Contents

1.Antifungal Drugs Market Report Introduction

2. Antifungal Drugs Market Executive Summary

• 2.1. Scope of the Study
• 2.2. Market at Glance
• 2.3. Competitive Assessment

3. Regulatory Analysis

4. Antifungal Drugs Market Key Factors Analysis

• 4.1. Antifungal Drugs Market Drivers
  • 4.1.1. Growing prevalence of various fungal infections
  • 4.1.2. An increasing number of antifungal drugs as over-the-counter (OTC)
  • 4.1.3. Surging incidence of nosocomial infections worldwide
  • 4.1.4. Increasing product innovations, such as the development of synthetic and semi-synthetic azole-based compounds for the treatment of invasive fungal infections
• 4.2. Antifungal Drugs Market Restraints and Challenges
  • 4.2.1. Increasing resistance to antifungal drugs
  • 4.2.2. Side effects of antifungal drugs
• 4.3. Antifungal Drugs Market Opportunities
  • 4.3.1. Availability of a robust product portfolio of antifungal drugs in various emerging countries

5. Antifungal Drugs Market Porter's Five Forces Analysis

• 5.1. Bargaining Power of Suppliers
• 5.2. Bargaining Power of Consumers
• 5.3. Threat of New Entrants
• 5.4. Threat of Substitutes
• 5.5. Competitive Rivalry

6. COVID-19 Impact Analysis on Antifungal Drugs Market

7. Antifungal Drugs Market Layout

• 7.1. By Indication
  • 7.1.1. Aspergillosis
  • 7.1.2. Dermatophytosis
  • 7.1.3. Candidiasis
  • 7.1.4. Others
• 7.2. By Drug Type
  • 7.2.1. Echinocandins
    • 7.2.1.1. Caspofungin
    • 7.2.1.2. Micafungin
    • 7.2.1.3. Others
  • 7.2.2. Azoles
    • 7.2.2.1. Voriconazole
    • 7.2.2.2. Posaconazole
    • 7.2.2.3. Clotrimazole
    • 7.2.2.4. Others
  • 7.2.3. Polyenes
    • 7.2.3.1. Amphotericin (AmBisome)
    • 7.2.3.2. Others
  • 7.2.4. Allylamines
    • 7.2.4.1. Terbinafine
    • 7.2.4.2. Others
  • 7.2.5. Others
• 7.3. By Dosage Form
  • 7.3.1. Powder
  • 7.3.2. Ointments
  • 7.3.3. Tablets
  • 7.3.4. Others
• 7.4. By Geography
  • 7.4.1. North America
    • 7.4.1.1. United States Antifungal Drugs Market in USD million (2021-2030)
    • 7.4.1.2. Canada Antifungal Drugs Market in USD million (2021-2030)
    • 7.4.1.3. Mexico Antifungal Drugs Market in USD million (2021-2030)
  • 7.4.2. Europe
    • 7.4.2.1. France Antifungal Drugs Market in USD million (2021-2030)
    • 7.4.2.2. Germany Antifungal Drugs Market in USD million (2021-2030)
    • 7.4.2.3. United Kingdom Antifungal Drugs Market in USD million (2021-2030)
    • 7.4.2.4. Italy Antifungal Drugs Market in USD million (2021-2030)
    • 7.4.2.5. Spain Antifungal Drugs Market in USD million (2021-2030)
    • 7.4.2.6. Rest of Europe Antifungal Drugs Market in USD million (2021-2030)
  • 7.4.3. Asia-Pacific
    • 7.4.3.1. China Antifungal Drugs Market in USD million (2021-2030)
    • 7.4.3.2. Japan Antifungal Drugs Market in USD million (2021-2030)
    • 7.4.3.3. India Antifungal Drugs Market in USD million (2021-2030)
    • 7.4.3.4. Australia Antifungal Drugs Market in USD million (2021-2030)
    • 7.4.3.5. South Korea Antifungal Drugs Market in USD million (2021-2030)
    • 7.4.3.6. Rest of Asia Pacific Antifungal Drugs Market in USD million (2021-2030)
  • 7.4.4. Rest of the World (RoW)
    • 7.4.4.1. Middle East Antifungal Drugs Market in USD million (2021-2030)
    • 7.4.4.2. Africa Antifungal Drugs Market in USD million (2021-2030)
    • 7.4.4.3. South America Antifungal Drugs Market in USD million (2021-2030)

8. Antifungal Drugs Market Company and Product Profiles

• 8.1. Abbott.
  • 8.1.1. Company Overview
  • 8.1.2. Company Snapshot
  • 8.1.3. Financial Overview
  • 8.1.4. Product Listing
  • 8.1.5. Entropy
• 8.2. Bayer AG
  • 8.2.1. Company Overview
  • 8.2.2. Company Snapshot
  • 8.2.3. Financial Overview
  • 8.2.4. Product Listing
  • 8.2.5. Entropy
• 8.3. GSK plc.
  • 8.3.1. Company Overview
  • 8.3.2. Company Snapshot
  • 8.3.3. Financial Overview
  • 8.3.4. Product Listing
  • 8.3.5. Entropy
• 8.4. Merck & Co., Inc.
  • 8.4.1. Company Overview
  • 8.4.2. Company Snapshot
  • 8.4.3. Financial Overview
  • 8.4.4. Product Listing
  • 8.4.5. Entropy
• 8.5. Cadila Pharmaceuticals.
  • 8.5.1. Company Overview
  • 8.5.2. Company Snapshot
  • 8.5.3. Financial Overview
  • 8.5.4. Product Listing
  • 8.5.5. Entropy
• 8.6. Glenmark
  • 8.6.1. Company Overview
  • 8.6.2. Company Snapshot
  • 8.6.3. Financial Overview
  • 8.6.4. Product Listing
  • 8.6.5. Entropy
• 8.7. SCYNEXIS, Inc.
  • 8.7.1. Company Overview
  • 8.7.2. Company Snapshot
  • 8.7.3. Financial Overview
  • 8.7.4. Product Listing
  • 8.7.5. Entropy
• 8.8. Astellas Pharma d.o.o.
  • 8.8.1. Company Overview
  • 8.8.2. Company Snapshot
  • 8.8.3. Financial Overview
  • 8.8.4. Product Listing
  • 8.8.5. Entropy
• 8.9. Arcadia Consumer Healthcare
  • 8.9.1. Company Overview
  • 8.9.2. Company Snapshot
  • 8.9.3. Financial Overview
  • 8.9.4. Product Listing
  • 8.9.5. Entropy
• 8.10. Novartis AG
  • 8.10.1. Company Overview
  • 8.10.2. Company Snapshot
  • 8.10.3. Financial Overview
  • 8.10.4. Product Listing
  • 8.10.5. Entropy
• 8.11. Pfizer Inc.
  • 8.11.1. Company Overview
  • 8.11.2. Company Snapshot
  • 8.11.3. Financial Overview
  • 8.11.4. Product Listing
  • 8.11.5. Entropy
• 8.12. Leadiant Biosciences, Inc.
  • 8.12.1. Company Overview
  • 8.12.2. Company Snapshot
  • 8.12.3. Financial Overview
  • 8.12.4. Product Listing
  • 8.12.5. Entropy
• 8.13. Sun Pharmaceutical Industries Ltd.
  • 8.13.1. Company Overview
  • 8.13.2. Company Snapshot
  • 8.13.3. Financial Overview
  • 8.13.4. Product Listing
  • 8.13.5. Entropy
• 8.14. Viatris Inc.
  • 8.14.1. Company Overview
  • 8.14.2. Company Snapshot
  • 8.14.3. Financial Overview
  • 8.14.4. Product Listing
  • 8.14.5. Entropy
• 8.15. Sanofi
  • 8.15.1. Company Overview
  • 8.15.2. Company Snapshot
  • 8.15.3. Financial Overview
  • 8.15.4. Product Listing
  • 8.15.5. Entropy
• 8.16. Gilead Sciences, Inc.
  • 8.16.1. Company Overview
  • 8.16.2. Company Snapshot
  • 8.16.3. Financial Overview
  • 8.16.4. Product Listing
  • 8.16.5. Entropy
• 8.17. Apotex Inc.
  • 8.17.1. Company Overview
  • 8.17.2. Company Snapshot
  • 8.17.3. Financial Overview
  • 8.17.4. Product Listing
  • 8.17.5. Entropy
• 8.18. Aurobindo Pharma USA
  • 8.18.1. Company Overview
  • 8.18.2. Company Snapshot
  • 8.18.3. Financial Overview
  • 8.18.4. Product Listing
  • 8.18.5. Entropy
• 8.19. Cipla Inc.
  • 8.19.1. Company Overview
  • 8.19.2. Company Snapshot
  • 8.19.3. Financial Overview
  • 8.19.4. Product Listing
  • 8.19.5. Entropy
• 8.20. Dr. Reddy's Laboratories Ltd.
  • 8.20.1. Company Overview
  • 8.20.2. Company Snapshot
  • 8.20.3. Financial Overview
  • 8.20.4. Product Listing
  • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us